Form 4: Cabaletta Bio Director Catherine Bollard Acquires 22,000 Stock Options

Director Catherine Bollard acquired 22,000 stock options in Cabaletta Bio, Inc. on June 3, 2024.

Summary

• Catherine Bollard, a director of Cabaletta Bio, Inc., reported a transaction on June 3, 2024.
• Bollard acquired 22,000 stock options with an exercise price of $10.01.
• These options vest fully on the earlier of June 3, 2025, or the date of the next annual meeting of the Corporation's stockholders.
• Following the transaction, Bollard directly owns 22,000 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction by a company director. The acquisition of stock options could be interpreted as a positive sign, but without further context, it's difficult to assign a strong positive sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.

Key Dates